AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 880
- Registration Number
- NCT06692738
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 172
- Registration Number
- NCT06692764
- Locations
- 🇺🇸
Research Site, Paris, Texas, United States
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT06681324
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11300
- Registration Number
- NCT06677060
- Locations
- 🇹🇭
Research Site, Ubonratchathani, Thailand
Observational Study on the Treatment of Patients With Metastatic Breast Cancer
Not yet recruiting
- Conditions
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06676436
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
Not yet recruiting
- Conditions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 438
- Registration Number
- NCT06675552
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT06675175
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06673043
A Study to Investigate the Pharmacokinetics of AZD0780 When Administered Alone and in Combination With Itraconazole and Carbamazepine in Healthy Participants Aged 18 to 75 Years of Age
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT06671405
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT06661733
- Locations
- 🇧🇬
Research Site, Sofia, Bulgaria
© Copyright 2024. All Rights Reserved by MedPath